1. Hz, 39 (m, J = 8.18 Hz, J = 1.02 Hz, 1H) Anal. (C 28 H 36 N 4 O 3 ) C, H, N. 1-sec-Butyl-N-[[1-(2-phenylethyl)-4-piperidinyl]methyl]-1H-inda- zole-3-carboxamide (11n). 11l (15.8 g, 44 mmol) was added into a stirred suspension of NaH (1.76 g, 60% suspension in mineral oil) in DMF (100 mL) cooled at 0 °C. The mixture was stirred at room temperature for 1 h, and then 2-bromobutane (6 mL, 44 mmol) was added. After 24 h at the same temperature, water (200 mL) was added, the solution was filtered, and the solid was dissolved in ethyl acetate. The residual inorganic material was filtered off, and the solution was concentrated under vacuum and treated with Et 2 O/HCl. The hydrochloride that formed was recrystallized from ethanol IR (KBr): ? 3327, 1H), pp.7-22

2. , 2. °c-c, H. , and N. , 13 C NMR (DMSO-d 6 ): ? 22 2-Methyl-2H-pyrrolo[3,4-c]quinolin-4(5H)-one (25) Methyl iodide (1.5 g, 11 mmol) and anhydrous potassium carbonate (1.5 g, 11 mmol) were added into a solution of 24 (2.0 g, 11 mmol) in anhydrous DMF (10 mL) The mixture was stirred at 90 °C for 15 h. After cooling, the reaction mixture was treated with water (30 mL) and filtered. The solid obtained was purified by column chromatography on silica gel (chloroform/methanol mixture (10:1) as eluent) to give 1.0 g of 25 (46%, sublimes at 225 °C, from toluene). 1 H NMR Journal of Medicinal Chemistry Article dx.doi.org/10)-one (26) To a solution of 24 (3.0 g, 16 mmol) in dioxane (150 mL) brought to reflux was added potassium metal (580 mg, 15 mmol), and the mixture was stirred at reflux until total disappearance of the metal was observed (2 h) After cooling, 2-iodopropane (2.8 g, 16 mmol) and 18-crown-6 ether (3.9 g, 15 mmol) were added, and the mixture was refluxed for 5.5 h. A further portion of 2-iodopropane (1.4 g, 8.1 mmol) was then added, and the reaction mixture was stirred at reflux for a further 15 h. After cooling, the dioxane was removed under reduced pressure, and the residue was taken up in ethyl acetate (100 mL) and washed with brine (3 × 50 mL) The organic solution was dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure to obtain a crude product, which was purified by column chromatography of aluminum oxide (ethyl acetate as eluent, Crude 11o was treated with 2.5 N HCl in ethanol solution to give the corresponding hydrochloride 4.50 (t, J = 7.31 Hz, 2H), 2.63?4.04 (m, 10H), 1.26?2.27 (m, 8H), 0.94 (d, J = 6.21 Hz, 6H)09. Anal. (C 27 H 36 N 4 O·HCl) 9446?9466 (DMSO-d 6 ): ? 3.91 (s, 3H), 7.09?7.25 (m, 3H), 7.58?7.81 (m, 3H), 10.73 (s, 1H). Anal. (C 12 H 10 N 2 O) C, H 1H). Anal. (C 14 H 14 N 2 O) C, H, N. 1-Acetyl-N-[[1-(2-phenylethyl)-4-piperidinyl]methyl]-1H-inda- zole-3-carboxamide (11p). Acetic anhydride (0.26 mL, 2.75 mmol) was added into a suspension of 11l (500 mg, 1.4 mmol) in CH 2 Cl, p.51607762, 1021.

J. =. Hz, H. , and N. , 93 (m, J = 7.7 Hz, J = 1.2 Hz, 1H) Anal, The product was converted to the hydrochloride as described for the compound 12e (95%, 165?167 °C, from diisopropyl ether

C. Hz-13, H. Nmr-c, N. C. , H. , and N. , Acid (12g). 12g was prepared according to the procedure described for 11ab using ethanol as solvent (27%, 155? 166 °C, from ethanol) 1 H NMR (DMF-d 7 ): ? 108 (m, 1H), 14?16 (br s, 1H))oxy]methyl]-1- piperidinyl]ethyl]benzoic Acid (12h). 12h was prepared according to the procedure described for 11ab using ethanol as solvent (dd, 1 H). Anal A solution of ethyl 3-(2-nitrophenyl)propanoate (22) 35 (26.6 g, 120 mmol) and TosMIC (25.4 g, 130 mmol) in anhydrous dimethyl sulfoxide/ethyl ether (1:2; 450 mL) was added dropwise to a well-stirred suspension of 60% sodium hydride in paraffin (10.4 g, 260 mmol) in anhydrous ethyl ether (300 mL) under a stream of argon. After the addition, the mixture was stirred at room temperature for 25 min, water (500 mL) was then added, and the resulting solution was extracted, 2H), 1.93 (m, 3H), 2.23 (m, 2H), 2.74 (m, 2H), 2.97 (m, 2H), 3.17 (m, 2H), 3.25 (m, 2H), 4.13 (s, 3H), 4.48 (d, 2H), 7.36 (m, 1H), 7.43 (m, 1H)50%, 165 °C, from ethyl acetate). 1 H NMR (DMF-d 7 ): ? 1.30 (m, 2H), 1.51 (m, 2H), 1.79?1.82 (m, 1 H), 2.51 (m, 5H):1) as eluent) to give 12.8 g of 23 (41%, 159?161 °C, from ethanol). 1 H NMR (CDCl 3 ): ? 2.51 (m, 3H), 4.01 (q, 2H), 6.51 (m, 1H), 7.31?7.33 (m, 1H), 7.39?7.41 (m, 2H), 7.49?7.53 (m, 1H), pp.1-08, 2002.

C. , H. , N. 2h-pyrrolorodrìguez, M. L. Morcillo, M. J. Benhamu? et al., Anal Iron powder (6.7 g, 120 mmol) was added over 15 min into a solution0 g, 7.7 mmol) in glacial acetic acid (100 mL) mechanically stirred at 85 °C. The mixture was stirring at the same temperature for 45 min After cooling, the iron was removed by filtration and washed several times with tetrahydrofuran, and the filtrate was evaporated under reduced pressure. The crude product was purified by column chromatography on aluminum oxide (ethyl acetate as eluent) to give 1.1 g of 24 (77%, sublimes at 280 °C from ethanol). 1 H NMR (DMSO-d 6 ): ? 7 (s, 1H). Anal. (C 11 H 8 N 2 O) C, H, N. 4-Chloro-2-methyl-2H-pyrrolo A mixture of product, 92?7.9405?7.28 (m, 3H), 7.57?7.63 (m, 2H), 7.84?7.88 (m, 1H), 10.7 (s, 1H) phosphorus oxychloride (16.2 mL), and triethylamine (1.2 mL) was stirred at 120 °C for 6 h. After cooling, the reaction mixture was poured cautiously into ice and extracted with Journal of Medicinal Chemistry, pp.9446-9466, 2012.

M. L. Rosado, Comparative receptor mapping of serotoninergic 5-HT 3

M. L. Lo?pezlo?pez-rodriguez, . Benhamu?, B. Benhamu?, M. J. Morcillo, M. Murcia et al., (4) receptor antagonists: structure-affinity relationships and ligand-receptor interactions, and 5-HT 4 binding sites 625?641. (15) Bureau, R.; Daveu, p.5, 1997.

G. Pepeu, F. Gualtieri, A. Bartolini, G. J. Doak, J. E. Sawynok et al., Central cholinergic antinociception induced by 5HT4 agonists: BIMU1 and BIMU8 Formalin-induced nociceptive behaviour and edema: involvement of multiple peripheral 5- hydroxytryptamine receptor subtypes Antagonism of peripheral 5-HT 4 receptors reduces visceral and cutaneous pain in mice, and induces visceral analgesia after simultaneous inactivation of 5-HT 3 receptors, 2297?2309. (17) 939?949. (18) Espejo, 1996.

E. Pecher, B. Nault, P. Ruegg, A. Tegaserod-hinschberger, S. Butt et al., 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation,6]naphthyridine and azepino[3,2-c]quinoline derivatives as selective antagonists of 5-HT4 receptors: binding profile and pharmacological characterization, 138?147. (21) Lemaitre, 2001.

F. Lezoualc-'h, B. Pfeiffer, F. Dauphin, S. Rault, J. H. De-maeyer et al., Novel antagonists of serotonin-4 receptors: synthesis and biological evaluation of pyrrolothienopyrazines A. 5-HT4 receptor agonists: similar but not the same The 5-HT 4 agonists cisapride, mosapride, and CJ-033466, a novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities Review article: cardiac adverse effects of gastrointestinal prokinetics, 207?210. (24)25) Leysen, J. E. 5-HT 2 receptors, pp.2607-2622, 1999.

D. Trudeau, M. C. Warmke, J. W. Ganetzky, B. Robertson, G. A. Talarico et al., HERG, a human inward rectifier in the voltage-gated potassium channel family, 92?95. (27) Wysowski, pp.11-26, 1995.
DOI : 10.1126/science.7604285

E. M. Rodriguez, B. Fermini, and A. A. Fossa, Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions The impact of drug-induced QT interval prolongation on drug discovery and development Synthesis and structure-activity relationships of potent and orally active 5-HT4 receptor antagonists: indazole and benzimidazolone derivatives, 439?447. (29) Schaus, pp.1698-1703, 1998.

M. Bingham, S. Ellis, E. S. Sanger, G. J. Wardle, and K. A. , -Butyl-4- piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-car- boxamide hydrochloride: the first potent and selective 5-HT 4 receptor antagonist amide with oral activity, Preparation of indazoleamide compounds as serotoninergic agents, pp.4760-4763, 1995.
URL : https://hal.archives-ouvertes.fr/hal-01156341

C. M. Gauss, A. Tehim, T. Inoue, and S. Watanabe, Preparation of quinuclidine indazole, benzothiazole, benzisothiazole and benzisoxazoles as ligands for the ?7 nicotinic acetylcholine receptor, PCT Int. Appl. WO, issue.33, 2005.

K. Shimada, E. L. Foreman, S. M. Mcelvain, R. Di-santo, R. Costi et al., Reaction of organic halides with piperidine. V. Negatively substituted ethyl bromides A general, versatile synthesis of 2H-pyrrolo[3,4-c]quinolines via tosylmethylisocyanide reaction Millois Barbuis, C. Preparation of bi-aromatic compounds, particularly 4-[(3-aminocarbonylhydrazono-2-oxo-2,3- dihydro-1H-indol-5-yl)sulfanylalkyl]benzoic acid derivatives, as PPAR modulators, and their use in cosmetic and pharmaceutical compositions, No. v, 181?195. (36), pp.1435-1438, 1940.

G. W. Gullikson, SC-53606, a potent and selective antagonist of 5- hydroxytryptamine 4 receptors in isolated rat esophageal tunica muscularis mucosae) The functional hERG/Kv11.1 potassium ion channel assay was performed at, ). (39) Mialet, 1993.

P. Eftekhari, J. Hoebeke, S. Sicsic, M. Langlois, and R. Fishmeister, Exploration of the ligand binding site of the human 5-HT4 receptor by site-directed mutagenesis and molecular modeling, 527?538. (40) Rivail, 2000.

L. Fishmeister, R. Lezoualc-'h, F. Maigret, B. Sicsic, S. Bojarski et al., Berque- Bestel, I. New insights into the human 5-HT 4 receptor binding site: exploration of a hydrophobic pocket Pharmacophore models for metabotropic 5-HT receptor ligands (42) Gleeson, M. P. Generation of a set of simple, interpretable ADMET rules of thumb, 817?834. (43) Zhu, B. Y.; Jia Inhibitory effect of carboxylic acid group on hERG binding, pp.361-370, 2004.

J. Klaveness and F. Levy, The large in vitro pharmacologic profile was performed at Ricerca Biosciences) on the following assays: (receptor binding) adrenergic ?1 (nonselective) (rat), adrenergic ?1A (rat), adrenergic ?1B (rat), adrenergic ?1D (human), chemokine CCR2B (human), cholecystokinin CK1 (CCKA) (human), cholecystokinin CCK2 (CCKB) (human), muscarinic nonselective (rat), muscarinic oxotremorine M (rat), serotonin 5-HT1A (human), serotonin 5- HT1B (rat), serotonin 5-HT2A (human), serotonin 5-HT2B (human), serotonin 5-HT2C (human), serotonin 5-HT3 (human), serotonin 5-HT4 (guinea pig), serotonin 5-HT5A (human), serotonin 5-HT6 (human), serotonin, sodium channel, site 2 (rat), serotonin transporter (SERT) (human), pp.5-7, 2010.

R. S. Obach, D. Leimbach, D. Dubuisson, and S. G. Dennis, Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and non specific binding to microsomes Synthetic analgesics. II. Dithienylbutenyl-and dithienylbutylamines The formalin test: a quantitative study of the analgesic effects of morphine, meperidine and brain stem stimulation in rats and cats. Pain 1977, 4, 161?174. (50) Irwin, S. Comprehensive observational assessment: a systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse Primary observation (Irwin) test in rodents for assessing acute toxicity of a test agent and its effect on behaviour and physiological function, 1350?1359. (48) Eddy, 222?257. (51) Roux, S.; Sable Current Protocols in Pharmacology, pp.477-486, 1953.

S. L. Dixon, A. M. Smondyrev, E. H. Knoll, S. N. Rao, D. E. Shaw et al., PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results, Journal of Computer-Aided Molecular Design, vol.5, issue.10-11, pp.1-23, 2006.
DOI : 10.1007/s10822-006-9087-6

L. L. Frye, W. T. Pollard, . Banks, J. L. Glide, G. Woolfe et al., A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening The evaluation of the analgesic action of pethidine hydrochloride (DEMEROL), 1750?1759. (54), p.47, 2004.

T. Maione, F. Bonito, M. C. Piscopo, A. Di-giannuario, A. Pieretti et al., New insights of dimethyl sulphoxide effects (DMSO) on experimental in vivo models of nociception and inflammation, Pharmacol. Res. Journal of Medicinal Chemistry Article J. Med. Chem, vol.80, issue.55, pp.419-425, 1944.